We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 01, 2020

First-Line Avelumab Plus Axitinib vs Sunitinib in Patients With Advanced Renal Cell Carcinoma

Annals of Oncology


Additional Info

Annals of Oncology
Updated Efficacy Results From the JAVELIN Renal 101 Trial: First-Line Avelumab Plus Axitinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma
Ann. Oncol 2020 Apr 24;[EPub Ahead of Print], TK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, C Kollmannsberger, G Gravis-Mescam, M Uemura, JL Lee, MO Grimm, H Gurney, M Schmidinger, J Larkin, MB Atkins, SK Pal, J Wang, M Mariani, S Krishnaswami, P Cislo, A Chudnovsky, C Fowst, B Huang, A di Pietro, L Albiges

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading